News
Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...
Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.
